Supernus Pharmaceuticals, Inc. (SUPN)

Supernus Pharmaceuticals Stock Forecast

Stock Price Forecast

The 2 analysts with 12-month price forecasts for Supernus Pharmaceuticals stock have an average target of 36, which predicts a 1.38% increase from the current stock price of 35.51.

Price Target: $36.00 (+1.38%)

Analyst Consensus: Hold

Target	Low	Average	Median	High
Price	$36	$36	$36	$36
Change	+1.38%	+1.38%	+1.38%	+1.38%

* Price targets were last updated on Feb 26, 2025.

Analyst Ratings

The average analyst rating for Supernus Pharmaceuticals stock is "Hold". This means that analysts believe this stock is likely to perform similarly to the overall market.

Recommendation Trends

Rating	Feb '25	Mar '25	Apr '25	May '25	Jun '25	Jul '25
Strong Buy	0	0	0	0	0	0
Buy	0	0	0	0	0	0
Hold	2	2	2	2	2	2
Sell	0	0	0	0	0	0
Strong Sell	0	0	0	0	0	0
Total	2	2	2	2	2	2

Latest Forecasts

Analyst	Firm	Rating	Rating	Action	Price Target	Upside	Date
Kristen Kluska Cantor Fitzgerald	Cantor Fitzgerald	Hold Reiterates $36	Hold	Reiterates	$36	+1.38%	Feb 26, 2025
Kristen Kluska Cantor Fitzgerald	Cantor Fitzgerald	Buy → Hold Downgrades $57 → $36	Buy → Hold	Downgrades	$57 → $36	+1.38%	Feb 19, 2025
David Amsellem Piper Sandler	Piper Sandler	Buy → Hold Downgrades $41 → $36	Buy → Hold	Downgrades	$41 → $36	+1.38%	Sep 11, 2024
David Amsellem Piper Sandler	Piper Sandler	Buy Maintains $45 → $41	Buy	Maintains	$45 → $41	+15.46%	Feb 28, 2024
David Amsellem Piper Sandler	Piper Sandler	Buy Maintains $42 → $43	Buy	Maintains	$42 → $43	+21.09%	Nov 9, 2023

More Analyst Ratings

Financial Forecast

Revenue This Year

653.90M

Decreased by -1.20%

from 661.82M

Revenue Next Year

756.85M

Increased by 15.74%

from 653.90M

EPS This Year

1.73

Increased by 31.11%

from 1.32

EPS Next Year

2.41

Increased by 39.29%

from 1.73

Fiscal Year	FY 2020	FY 2021	FY 2022	FY 2023	FY 2024	FY 2025	FY 2026	FY 2027
Period Ending	Dec 31, 2020	Dec 31, 2021	Dec 31, 2022	Dec 31, 2023	Dec 31, 2024	Dec 31, 2025	Dec 31, 2026	Dec 31, 2027
Revenue	520.40M	579.78M	667.24M	607.52M	661.82M	653.90M	756.85M	849.60M
Revenue Growth	32.50%	11.41%	15.09%	-8.95%	8.94%	-1.20%	15.74%	12.25%
EPS	2.36	0.98	1.04	0.02	1.32	1.73	2.41	3.44
EPS Growth	12.38%	-58.48%	6.32%	-98.08%	6,500.00%	31.11%	39.29%	42.88%
Forward PE	-	-	-	-	-	20.52	14.73	10.31
No. Analysts	-	-	-	-	-	7	7	7

Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.

Revenue Forecast

Revenue	2025	2026	2027
High	693.0M	861.0M	1.0B
Avg	653.9M	756.9M	849.6M
Low	609.9M	672.2M	724.9M

Revenue Growth

Revenue Growth	2025	2026	2027
High	4.7%	31.7%	32.5%
Avg	-1.2%	15.7%	12.3%
Low	-7.9%	2.8%	-4.2%

EPS Forecast

EPS	2025	2026	2027	2028
High	2.21	2.82	3.83
Avg	1.73	2.41	3.44
Low	1.08	1.96	2.82

EPS Growth

EPS Growth	2025	2026	2027	2028
High	67.0%	63.2%	59.0%
Avg	31.1%	39.3%	42.9%
Low	-18.3%	13.3%	17.1%

Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.